Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Enhertu improved pCR in early-stage breast cancer | 7 May 2025 |
| Calquence combination approved in EU for 1L MCL | 6 May 2025 |
| Breztri met primary endpoints in Ph3 asthma trials | 2 May 2025 |
| Total Voting Rights | 1 May 2025 |
| Director/PDMR Shareholding | 1 May 2025 |
| 1st Quarter Results | 29 Apr 2025 |
| Update on CAPItello-280 Phase III trial | 29 Apr 2025 |
| Fixed-duration Calquence recommended in EU for CLL | 29 Apr 2025 |
| Enhertu combination improved PFS in 1L HER2+ mBC | 22 Apr 2025 |
| Result of AGM | 11 Apr 2025 |
| Enhertu approved in EU in post-ET breast cancer | 4 Apr 2025 |
| Imfinzi approved in EU for AEGEAN | 4 Apr 2025 |